Wednesday, August 27th, 2025
Stock Profile: CRNX
CRNX Logo

Crinetics Pharmaceuticals, Inc. (CRNX)

Market: NASD | Currency: USD

Address: 6055 Lusk Boulevard

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal Show more




📈 Crinetics Pharmaceuticals, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Crinetics Pharmaceuticals, Inc.


DateReported EPS
2025-11-10 (estimated upcoming)-
2025-08-07-1.23
2025-05-08-1.04
2025-02-27-0.88
2024-11-12-0.96
2024-08-08-0.94
2024-05-09-0.93
2024-02-28-0.9
2023-11-07-1.01
2023-08-08-0.94
2023-05-04-0.85
2023-02-28-0.84
2022-11-14-0.78
2022-08-12-0.81
2022-05-12-0.73
2022-03-30-0.68
2021-11-05-0.73
2021-08-10-0.7
2021-05-06-0.69
2021-03-30-0.66
2020-11-06-0.56
2020-08-07-0.53
2020-05-08-0.71
2020-03-09-0.6
2019-11-12-0.6




📰 Related News & Research


No related articles found for "crinetics pharmaceuticals".